nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Topotecan—peripheral nervous system neoplasm	0.135	0.219	CbGbCtD
Leflunomide—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.0934	0.152	CbGbCtD
Leflunomide—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0575	0.0934	CbGbCtD
Leflunomide—CYP1A2—Alitretinoin—peripheral nervous system neoplasm	0.0555	0.0902	CbGbCtD
Leflunomide—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0536	0.0871	CbGbCtD
Leflunomide—ABCG2—Etoposide—peripheral nervous system neoplasm	0.0527	0.0855	CbGbCtD
Leflunomide—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0465	0.0755	CbGbCtD
Leflunomide—CYP1A2—Dacarbazine—peripheral nervous system neoplasm	0.0444	0.0721	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0359	0.0583	CbGbCtD
Leflunomide—CYP1A2—Etoposide—peripheral nervous system neoplasm	0.0217	0.0353	CbGbCtD
Leflunomide—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0199	0.0323	CbGbCtD
Leflunomide—DHODH—Nucleotide metabolism—NME1—peripheral nervous system neoplasm	0.00497	0.0675	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.00365	0.0495	CbGpPWpGaD
Leflunomide—ABCG2—Abacavir transmembrane transport—ABCB1—peripheral nervous system neoplasm	0.00291	0.0395	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—BARD1—peripheral nervous system neoplasm	0.00228	0.0309	CbGpPWpGaD
Leflunomide—PTK2B—Signal regulatory protein (SIRP) family interactions—PTPN11—peripheral nervous system neoplasm	0.00207	0.028	CbGpPWpGaD
Leflunomide—PTK2B—Alpha-synuclein signaling—TH—peripheral nervous system neoplasm	0.00182	0.0247	CbGpPWpGaD
Leflunomide—ABCG2—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.0017	0.023	CbGpPWpGaD
Leflunomide—ABCG2—Abacavir transport and metabolism—ABCB1—peripheral nervous system neoplasm	0.00167	0.0227	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—NCAM1—peripheral nervous system neoplasm	0.0015	0.0203	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.00141	0.0191	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—HGF—peripheral nervous system neoplasm	0.00131	0.0178	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—MET—peripheral nervous system neoplasm	0.00104	0.0141	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.00102	0.0138	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000965	0.0131	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—PTPN11—peripheral nervous system neoplasm	0.000958	0.013	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—COX2—peripheral nervous system neoplasm	0.000929	0.0126	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000911	0.0124	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—HGF—peripheral nervous system neoplasm	0.000907	0.0123	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—BIRC5—peripheral nervous system neoplasm	0.000838	0.0114	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000824	0.0112	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000809	0.011	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000796	0.0108	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000767	0.0104	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000742	0.0101	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—PTPN11—peripheral nervous system neoplasm	0.000739	0.01	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—MET—peripheral nervous system neoplasm	0.000715	0.00971	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000686	0.00931	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—NCAM1—peripheral nervous system neoplasm	0.000683	0.00927	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000662	0.00898	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—PTPN11—peripheral nervous system neoplasm	0.000662	0.00898	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000661	0.00896	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000652	0.00884	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	0.000603	0.00818	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—PTPN11—peripheral nervous system neoplasm	0.000585	0.00793	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—NTRK2—peripheral nervous system neoplasm	0.000581	0.00788	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.00057	0.00774	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—PTPN11—peripheral nervous system neoplasm	0.00055	0.00746	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AURKA—peripheral nervous system neoplasm	0.000529	0.00717	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—HGF—peripheral nervous system neoplasm	0.000521	0.00707	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CDKN2A—peripheral nervous system neoplasm	0.000496	0.00673	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000476	0.00646	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—NTRK1—peripheral nervous system neoplasm	0.000473	0.00642	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GNS—peripheral nervous system neoplasm	0.000471	0.00639	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—ABCB1—peripheral nervous system neoplasm	0.000469	0.00637	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000469	0.00636	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—PTPN11—peripheral nervous system neoplasm	0.000465	0.0063	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000453	0.00615	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—NME1—peripheral nervous system neoplasm	0.000452	0.00613	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—NRAS—peripheral nervous system neoplasm	0.000445	0.00603	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.00044	0.00596	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—COX2—peripheral nervous system neoplasm	0.000435	0.0059	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—BDNF—peripheral nervous system neoplasm	0.000433	0.00588	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—HRAS—peripheral nervous system neoplasm	0.000421	0.00572	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—CASP3—peripheral nervous system neoplasm	0.000414	0.00562	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CASP3—peripheral nervous system neoplasm	0.000409	0.00555	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.000402	0.00545	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NCAM1—peripheral nervous system neoplasm	0.000401	0.00544	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—NRAS—peripheral nervous system neoplasm	0.000398	0.0054	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PTPN11—peripheral nervous system neoplasm	0.000383	0.00519	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—PTPN11—peripheral nervous system neoplasm	0.00038	0.00516	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.00038	0.00515	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MYC—peripheral nervous system neoplasm	0.000371	0.00503	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—ABCB1—peripheral nervous system neoplasm	0.00037	0.00502	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—PTPN11—peripheral nervous system neoplasm	0.000361	0.0049	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000356	0.00483	CbGpPWpGaD
Leflunomide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000333	0.00452	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—PTPN11—peripheral nervous system neoplasm	0.000328	0.00444	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—HRAS—peripheral nervous system neoplasm	0.000325	0.00441	CbGpPWpGaD
Leflunomide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000318	0.00431	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IFNB1—peripheral nervous system neoplasm	0.000315	0.00427	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000314	0.00426	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000302	0.0041	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000297	0.00402	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—HRAS—peripheral nervous system neoplasm	0.000291	0.00395	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ENO2—peripheral nervous system neoplasm	0.000286	0.00387	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PTPN11—peripheral nervous system neoplasm	0.000275	0.00373	CbGpPWpGaD
Leflunomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000271	0.00368	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000262	0.00356	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—peripheral nervous system neoplasm	0.000261	0.00354	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—HRAS—peripheral nervous system neoplasm	0.000257	0.00349	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—AKT1—peripheral nervous system neoplasm	0.000257	0.00349	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—peripheral nervous system neoplasm	0.000254	0.00345	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000251	0.0034	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000244	0.0033	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HGF—peripheral nervous system neoplasm	0.000243	0.0033	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—BCHE—peripheral nervous system neoplasm	0.000241	0.00327	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—AKT1—peripheral nervous system neoplasm	0.000233	0.00316	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NRAS—peripheral nervous system neoplasm	0.00023	0.00312	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.00023	0.00312	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—NRAS—peripheral nervous system neoplasm	0.000228	0.0031	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—AKT1—peripheral nervous system neoplasm	0.000227	0.00308	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—AKT1—peripheral nervous system neoplasm	0.000227	0.00308	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—TH—peripheral nervous system neoplasm	0.000227	0.00308	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—AKT1—peripheral nervous system neoplasm	0.000224	0.00304	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000222	0.00301	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—NRAS—peripheral nervous system neoplasm	0.000217	0.00295	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ERBB2—peripheral nervous system neoplasm	0.000217	0.00295	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CASP3—peripheral nervous system neoplasm	0.000217	0.00294	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—peripheral nervous system neoplasm	0.000214	0.0029	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.00021	0.00285	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000206	0.00279	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD55—peripheral nervous system neoplasm	0.000203	0.00276	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000194	0.00263	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000193	0.00262	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	0.000186	0.00253	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GNAS—peripheral nervous system neoplasm	0.000185	0.00251	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000182	0.00247	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—peripheral nervous system neoplasm	0.00018	0.00245	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PTPN11—peripheral nervous system neoplasm	0.000177	0.00241	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000171	0.00232	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—peripheral nervous system neoplasm	0.000168	0.00228	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—peripheral nervous system neoplasm	0.000167	0.00227	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—peripheral nervous system neoplasm	0.000159	0.00216	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000156	0.00212	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD34—peripheral nervous system neoplasm	0.000154	0.00209	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00015	0.00204	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	0.000149	0.00202	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000148	0.00201	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	0.00014	0.0019	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000137	0.00186	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	0.000133	0.0018	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000131	0.00178	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NCAM1—peripheral nervous system neoplasm	0.000131	0.00178	CbGpPWpGaD
Leflunomide—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000123	0.000398	CcSEcCtD
Leflunomide—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000123	0.000398	CcSEcCtD
Leflunomide—Pain—Cisplatin—peripheral nervous system neoplasm	0.000123	0.000397	CcSEcCtD
Leflunomide—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000392	CcSEcCtD
Leflunomide—Dysuria—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000392	CcSEcCtD
Leflunomide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000121	0.000391	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000121	0.00039	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	0.000121	0.00164	CbGpPWpGaD
Leflunomide—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000388	CcSEcCtD
Leflunomide—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000388	CcSEcCtD
Leflunomide—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000388	CcSEcCtD
Leflunomide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.00012	0.000387	CcSEcCtD
Leflunomide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.00012	0.000386	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00012	0.00162	CbGpPWpGaD
Leflunomide—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000119	0.000384	CcSEcCtD
Leflunomide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000119	0.000383	CcSEcCtD
Leflunomide—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000119	0.000382	CcSEcCtD
Leflunomide—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000381	CcSEcCtD
Leflunomide—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000118	0.00038	CcSEcCtD
Leflunomide—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000118	0.00038	CcSEcCtD
Leflunomide—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000379	CcSEcCtD
Leflunomide—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000117	0.000378	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	0.000117	0.00159	CbGpPWpGaD
Leflunomide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000117	0.000377	CcSEcCtD
Leflunomide—Pneumonia—Epirubicin—peripheral nervous system neoplasm	0.000117	0.000376	CcSEcCtD
Leflunomide—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000374	CcSEcCtD
Leflunomide—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000116	0.000374	CcSEcCtD
Leflunomide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000116	0.000374	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.000373	CcSEcCtD
Leflunomide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000116	0.000373	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000371	CcSEcCtD
Leflunomide—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000115	0.000371	CcSEcCtD
Leflunomide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000115	0.00037	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000114	0.000369	CcSEcCtD
Leflunomide—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000368	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000114	0.000368	CcSEcCtD
Leflunomide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000114	0.000367	CcSEcCtD
Leflunomide—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000114	0.000367	CcSEcCtD
Leflunomide—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000367	CcSEcCtD
Leflunomide—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000365	CcSEcCtD
Leflunomide—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000365	CcSEcCtD
Leflunomide—Constipation—Etoposide—peripheral nervous system neoplasm	0.000113	0.000364	CcSEcCtD
Leflunomide—Pain—Etoposide—peripheral nervous system neoplasm	0.000113	0.000364	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000364	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000364	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000363	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000363	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000361	CcSEcCtD
Leflunomide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000112	0.000361	CcSEcCtD
Leflunomide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000112	0.00036	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000359	CcSEcCtD
Leflunomide—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000357	CcSEcCtD
Leflunomide—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000354	CcSEcCtD
Leflunomide—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.00011	0.000353	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000351	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000351	CcSEcCtD
Leflunomide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000109	0.000351	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.00035	CcSEcCtD
Leflunomide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000108	0.000349	CcSEcCtD
Leflunomide—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000108	0.000349	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—peripheral nervous system neoplasm	0.000108	0.000348	CcSEcCtD
Leflunomide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000108	0.000348	CcSEcCtD
Leflunomide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000108	0.000348	CcSEcCtD
Leflunomide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000108	0.000347	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000346	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000346	CcSEcCtD
Leflunomide—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.000344	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000107	0.00145	CbGpPWpGaD
Leflunomide—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000107	0.000344	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	0.000107	0.00145	CbGpPWpGaD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	0.000107	0.000343	CcSEcCtD
Leflunomide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000106	0.000342	CcSEcCtD
Leflunomide—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000106	0.000342	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.00034	CcSEcCtD
Leflunomide—ABCG2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000105	0.00143	CbGpPWpGaD
Leflunomide—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000339	CcSEcCtD
Leflunomide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000105	0.000338	CcSEcCtD
Leflunomide—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000338	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000337	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000337	CcSEcCtD
Leflunomide—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000337	CcSEcCtD
Leflunomide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000104	0.000337	CcSEcCtD
Leflunomide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000104	0.000337	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000336	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000336	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000336	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000336	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000104	0.00141	CbGpPWpGaD
Leflunomide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000104	0.000334	CcSEcCtD
Leflunomide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000104	0.000333	CcSEcCtD
Leflunomide—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000333	CcSEcCtD
Leflunomide—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000332	CcSEcCtD
Leflunomide—Rash—Vincristine—peripheral nervous system neoplasm	0.000103	0.000331	CcSEcCtD
Leflunomide—PTK2B—Immune System—IFNB1—peripheral nervous system neoplasm	0.000103	0.0014	CbGpPWpGaD
Leflunomide—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000103	0.000331	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000331	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.00033	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000102	0.00033	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000329	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000102	0.00139	CbGpPWpGaD
Leflunomide—Headache—Vincristine—peripheral nervous system neoplasm	0.000102	0.000329	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	0.000102	0.00138	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000327	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000327	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000325	CcSEcCtD
Leflunomide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000101	0.000324	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.0001	0.000323	CcSEcCtD
Leflunomide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	9.87e-05	0.000318	CcSEcCtD
Leflunomide—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	9.86e-05	0.000318	CcSEcCtD
Leflunomide—Eye disorder—Epirubicin—peripheral nervous system neoplasm	9.74e-05	0.000314	CcSEcCtD
Leflunomide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	9.74e-05	0.000314	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	9.7e-05	0.000312	CcSEcCtD
Leflunomide—Nausea—Vincristine—peripheral nervous system neoplasm	9.69e-05	0.000312	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	9.68e-05	0.000312	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	9.67e-05	0.000312	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	9.65e-05	0.000311	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	9.65e-05	0.000311	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.59e-05	0.0013	CbGpPWpGaD
Leflunomide—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	9.58e-05	0.000308	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	9.53e-05	0.000307	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	9.5e-05	0.000306	CcSEcCtD
Leflunomide—Asthenia—Etoposide—peripheral nervous system neoplasm	9.48e-05	0.000305	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	9.48e-05	0.000305	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	9.46e-05	0.000305	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	9.42e-05	0.000303	CcSEcCtD
Leflunomide—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	9.4e-05	0.000303	CcSEcCtD
Leflunomide—Chills—Epirubicin—peripheral nervous system neoplasm	9.36e-05	0.000301	CcSEcCtD
Leflunomide—Pruritus—Etoposide—peripheral nervous system neoplasm	9.35e-05	0.000301	CcSEcCtD
Leflunomide—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	9.32e-05	0.0003	CcSEcCtD
Leflunomide—Alopecia—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000297	CcSEcCtD
Leflunomide—Vomiting—Cisplatin—peripheral nervous system neoplasm	9.17e-05	0.000295	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—peripheral nervous system neoplasm	9.14e-05	0.000294	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	9.12e-05	0.000294	CcSEcCtD
Leflunomide—Rash—Cisplatin—peripheral nervous system neoplasm	9.1e-05	0.000293	CcSEcCtD
Leflunomide—Dermatitis—Cisplatin—peripheral nervous system neoplasm	9.09e-05	0.000293	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—peripheral nervous system neoplasm	9.08e-05	0.000292	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	9.07e-05	0.00123	CbGpPWpGaD
Leflunomide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	9.04e-05	0.000291	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	9.02e-05	0.00029	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	8.95e-05	0.000288	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—peripheral nervous system neoplasm	8.94e-05	0.000288	CcSEcCtD
Leflunomide—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	8.89e-05	0.000286	CcSEcCtD
Leflunomide—Back pain—Epirubicin—peripheral nervous system neoplasm	8.78e-05	0.000283	CcSEcCtD
Leflunomide—Dizziness—Etoposide—peripheral nervous system neoplasm	8.74e-05	0.000281	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	8.73e-05	0.000281	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	8.71e-05	0.000281	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	8.7e-05	0.00028	CcSEcCtD
Leflunomide—Chills—Doxorubicin—peripheral nervous system neoplasm	8.66e-05	0.000279	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	8.62e-05	0.000278	CcSEcCtD
Leflunomide—Nausea—Cisplatin—peripheral nervous system neoplasm	8.57e-05	0.000276	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—peripheral nervous system neoplasm	8.55e-05	0.000276	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—peripheral nervous system neoplasm	8.53e-05	0.000275	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	8.45e-05	0.00115	CbGpPWpGaD
Leflunomide—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000272	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	8.42e-05	0.000271	CcSEcCtD
Leflunomide—Vomiting—Etoposide—peripheral nervous system neoplasm	8.4e-05	0.000271	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	8.4e-05	0.000271	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—peripheral nervous system neoplasm	8.39e-05	0.00027	CcSEcCtD
Leflunomide—Rash—Etoposide—peripheral nervous system neoplasm	8.33e-05	0.000268	CcSEcCtD
Leflunomide—Dermatitis—Etoposide—peripheral nervous system neoplasm	8.33e-05	0.000268	CcSEcCtD
Leflunomide—Headache—Etoposide—peripheral nervous system neoplasm	8.28e-05	0.000267	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—peripheral nervous system neoplasm	8.28e-05	0.000267	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	8.22e-05	0.000265	CcSEcCtD
Leflunomide—Malaise—Epirubicin—peripheral nervous system neoplasm	8.19e-05	0.000264	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—peripheral nervous system neoplasm	8.16e-05	0.000263	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—peripheral nervous system neoplasm	8.13e-05	0.000262	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—peripheral nervous system neoplasm	8.12e-05	0.000262	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	8.08e-05	0.00026	CcSEcCtD
Leflunomide—Palpitations—Epirubicin—peripheral nervous system neoplasm	8.02e-05	0.000258	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	7.95e-05	0.00108	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HGF—peripheral nervous system neoplasm	7.94e-05	0.00108	CbGpPWpGaD
Leflunomide—Cough—Epirubicin—peripheral nervous system neoplasm	7.92e-05	0.000255	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	7.92e-05	0.000255	CcSEcCtD
Leflunomide—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.89e-05	0.00107	CbGpPWpGaD
Leflunomide—Nausea—Etoposide—peripheral nervous system neoplasm	7.85e-05	0.000253	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—peripheral nervous system neoplasm	7.84e-05	0.000252	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	7.8e-05	0.00106	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	7.79e-05	0.000251	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—peripheral nervous system neoplasm	7.76e-05	0.00025	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—peripheral nervous system neoplasm	7.73e-05	0.000249	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	7.73e-05	0.000249	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—peripheral nervous system neoplasm	7.73e-05	0.000249	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—peripheral nervous system neoplasm	7.7e-05	0.000248	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	7.67e-05	0.000247	CcSEcCtD
Leflunomide—Discomfort—Epirubicin—peripheral nervous system neoplasm	7.64e-05	0.000246	CcSEcCtD
Leflunomide—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	7.62e-05	0.00103	CbGpPWpGaD
Leflunomide—Malaise—Doxorubicin—peripheral nervous system neoplasm	7.57e-05	0.000244	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000243	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—peripheral nervous system neoplasm	7.55e-05	0.000243	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	7.52e-05	0.000242	CcSEcCtD
Leflunomide—Palpitations—Doxorubicin—peripheral nervous system neoplasm	7.42e-05	0.000239	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	7.41e-05	0.000239	CcSEcCtD
Leflunomide—Infection—Epirubicin—peripheral nervous system neoplasm	7.36e-05	0.000237	CcSEcCtD
Leflunomide—Cough—Doxorubicin—peripheral nervous system neoplasm	7.33e-05	0.000236	CcSEcCtD
Leflunomide—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	7.31e-05	0.000992	CbGpPWpGaD
Leflunomide—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	7.27e-05	0.000234	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	7.25e-05	0.000234	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.000234	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—peripheral nervous system neoplasm	7.23e-05	0.000233	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7.2e-05	0.000977	CbGpPWpGaD
Leflunomide—Skin disorder—Epirubicin—peripheral nervous system neoplasm	7.2e-05	0.000232	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	7.16e-05	0.000231	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	7.15e-05	0.00023	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—peripheral nervous system neoplasm	7.15e-05	0.00023	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	7.15e-05	0.00023	CcSEcCtD
Leflunomide—Anxiety—Doxorubicin—peripheral nervous system neoplasm	7.13e-05	0.00023	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	7.1e-05	0.000229	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	7.06e-05	0.000228	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—peripheral nervous system neoplasm	7.06e-05	0.000227	CcSEcCtD
Leflunomide—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	7.04e-05	0.000955	CbGpPWpGaD
Leflunomide—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000225	CcSEcCtD
Leflunomide—Hypotension—Epirubicin—peripheral nervous system neoplasm	6.92e-05	0.000223	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	6.85e-05	0.000221	CcSEcCtD
Leflunomide—Infection—Doxorubicin—peripheral nervous system neoplasm	6.81e-05	0.000219	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	6.75e-05	0.000217	CcSEcCtD
Leflunomide—CYP1A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.74e-05	0.000914	CbGpPWpGaD
Leflunomide—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	6.72e-05	0.000217	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	6.71e-05	0.000216	CcSEcCtD
Leflunomide—Insomnia—Epirubicin—peripheral nervous system neoplasm	6.7e-05	0.000216	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	6.69e-05	0.000215	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	6.66e-05	0.000214	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	6.65e-05	0.000214	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	6.64e-05	0.000901	CbGpPWpGaD
Leflunomide—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	6.63e-05	0.000213	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	6.6e-05	0.000213	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	6.53e-05	0.00021	CcSEcCtD
Leflunomide—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	6.52e-05	0.00021	CcSEcCtD
Leflunomide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	6.44e-05	0.000207	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	6.41e-05	0.000206	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	6.4e-05	0.000868	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	6.4e-05	0.000206	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—peripheral nervous system neoplasm	6.39e-05	0.000206	CcSEcCtD
Leflunomide—Pain—Epirubicin—peripheral nervous system neoplasm	6.34e-05	0.000204	CcSEcCtD
Leflunomide—Constipation—Epirubicin—peripheral nervous system neoplasm	6.34e-05	0.000204	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	6.28e-05	0.000852	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	6.25e-05	0.000201	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—peripheral nervous system neoplasm	6.2e-05	0.0002	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.16e-05	0.000836	CbGpPWpGaD
Leflunomide—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	6.16e-05	0.000198	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	6.11e-05	0.000197	CcSEcCtD
Leflunomide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	6.1e-05	0.000197	CcSEcCtD
Leflunomide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	6.06e-05	0.000195	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	6.03e-05	0.000194	CcSEcCtD
Leflunomide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	5.96e-05	0.000192	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.92e-05	0.000191	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—peripheral nervous system neoplasm	5.91e-05	0.00019	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—peripheral nervous system neoplasm	5.89e-05	0.00019	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.87e-05	0.000797	CbGpPWpGaD
Leflunomide—Pain—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000189	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000189	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	5.86e-05	0.000189	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	5.86e-05	0.000189	CcSEcCtD
Leflunomide—PTK2B—Immune System—PTPN11—peripheral nervous system neoplasm	5.79e-05	0.000786	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	5.65e-05	0.000182	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	5.61e-05	0.000181	CcSEcCtD
Leflunomide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000176	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000175	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	5.42e-05	0.000175	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	5.42e-05	0.000175	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.39e-05	0.000731	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.33e-05	0.000723	CbGpPWpGaD
Leflunomide—Asthenia—Epirubicin—peripheral nervous system neoplasm	5.32e-05	0.000171	CcSEcCtD
Leflunomide—Pruritus—Epirubicin—peripheral nervous system neoplasm	5.24e-05	0.000169	CcSEcCtD
Leflunomide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	5.07e-05	0.000163	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000163	CcSEcCtD
Leflunomide—DHODH—Metabolism—AKT1—peripheral nervous system neoplasm	5e-05	0.000678	CbGpPWpGaD
Leflunomide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	4.92e-05	0.000158	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—peripheral nervous system neoplasm	4.9e-05	0.000158	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.85e-05	0.000156	CcSEcCtD
Leflunomide—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000152	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.69e-05	0.000151	CcSEcCtD
Leflunomide—Rash—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.00015	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.00015	CcSEcCtD
Leflunomide—Headache—Epirubicin—peripheral nervous system neoplasm	4.64e-05	0.000149	CcSEcCtD
Leflunomide—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	4.62e-05	0.000627	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—peripheral nervous system neoplasm	4.58e-05	0.000621	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.55e-05	0.000618	CbGpPWpGaD
Leflunomide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	4.53e-05	0.000146	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.43e-05	0.000601	CbGpPWpGaD
Leflunomide—Nausea—Epirubicin—peripheral nervous system neoplasm	4.4e-05	0.000142	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.00014	CcSEcCtD
Leflunomide—Rash—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000139	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000139	CcSEcCtD
Leflunomide—Headache—Doxorubicin—peripheral nervous system neoplasm	4.29e-05	0.000138	CcSEcCtD
Leflunomide—Nausea—Doxorubicin—peripheral nervous system neoplasm	4.07e-05	0.000131	CcSEcCtD
Leflunomide—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	3.9e-05	0.00053	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	3.85e-05	0.000522	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.78e-05	0.000513	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.74e-05	0.000508	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.72e-05	0.000505	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	3.69e-05	0.000501	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	3.67e-05	0.000498	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	3.55e-05	0.000482	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—peripheral nervous system neoplasm	3.48e-05	0.000472	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNS—peripheral nervous system neoplasm	3.29e-05	0.000446	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.16e-05	0.000428	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—COX2—peripheral nervous system neoplasm	3.04e-05	0.000412	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	3e-05	0.000406	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.96e-05	0.000402	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	2.94e-05	0.000399	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.69e-05	0.000364	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—peripheral nervous system neoplasm	2.55e-05	0.000346	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	2.33e-05	0.000317	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.25e-05	0.000305	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—peripheral nervous system neoplasm	2.25e-05	0.000305	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.1e-05	0.000285	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO2—peripheral nervous system neoplasm	1.99e-05	0.000271	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	1.97e-05	0.000267	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.88e-05	0.000255	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	1.85e-05	0.000251	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.72e-05	0.000234	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.68e-05	0.000229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.65e-05	0.000223	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.61e-05	0.000218	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TH—peripheral nervous system neoplasm	1.58e-05	0.000215	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.51e-05	0.000205	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.48e-05	0.000201	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.45e-05	0.000197	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.29e-05	0.000175	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.27e-05	0.000172	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	8.09e-06	0.00011	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	4.08e-06	5.54e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.49e-06	4.74e-05	CbGpPWpGaD
